Rubicon Technology (RBCN) 10-K 25 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 28, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	RUBICON TECHNOLOGY, INC.
Trading Symbol	RBCN
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		2,446,652
Entity Public Float			$ 19,082,840
Amendment Flag	false
Entity Central Index Key	0001410172
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-33834
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4419301
Entity Address, Address Line One	900 East Green Street
Entity Address, City or Town	Bensenville
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60106
City Area Code	(847)
Local Phone Number	295-7000
Title of 12(b) Security	Common Stock, par value $.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Name	Marcum llp
Auditor Firm ID	688
Auditor Location	Chicago, Illinois

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 11,260,000	$ 11,130,000
Short-term investments	14,751,000	14,748,000
Accounts receivable, net	719,000	386,000
Inventories	658,000	1,073,000
Other inventory supplies	133,000	140,000
Prepaid expenses and other current assets	167,000	284,000
Assets held for sale	529,000	529,000
Total current assets	28,217,000	28,290,000
Inventories, non-current	468,000	468,000
Property and equipment, net	2,301,000	2,482,000
Total assets	30,986,000	31,240,000
Liabilities and stockholders’ equity
Accounts payable	545,000	497,000
Accrued payroll	426,000	211,000
Accrued and other current liabilities	220,000	201,000
Corporate income and franchise taxes	327,000	307,000
Accrued real estate taxes	78,000	71,000
Advance payments	2,000	18,000
Total current liabilities	1,598,000	1,305,000
Commitments and contingencies (see Note 10)
Stockholders’ equity
Preferred stock, $0.001 par value, 1,000,000 undesignated shares authorized, no shares issued or outstanding
Common stock, $0.001 par value 8,200,000 shares authorized; 2,995,680 and 2,971,283 shares issued; 2,446,652 and 2,422,255 shares outstanding	29,000	29,000
Additional paid-in capital	376,640,000	376,456,000
Treasury stock, at cost, 549,028 and 549,028 shares	(15,147,000)	(15,147,000)
Accumulated other comprehensive loss	(1,000)
Accumulated deficit	(332,133,000)	(331,403,000)
Total stockholders’ equity	29,388,000	29,935,000
Total liabilities and stockholders’ equity	$ 30,986,000	$ 31,240,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	8,200,000	8,200,000
Common stock, shares issued	2,995,680	2,971,283
Common stock, shares outstanding	2,446,652	2,422,255
Treasury stock, shares	549,028	549,028

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 4,061	$ 3,616
Cost of goods sold	2,798	2,608
Gross profit	1,263	1,008
Operating expenses:
General and administrative	2,130	1,942
Sales and marketing	210	280
Gain on sale or disposal of assets and subsidiary	(613)	(2,084)
Income (loss) from continuing operations	(464)	870
Other (expense) income:
Interest income	5	108
Realized loss on marketable securities		(1,824)
Realized gain on foreign currency translation		136
Total other (expense) income	5	(1,580)
Loss before income taxes from continuing operations	(459)	(710)
Income tax expense		(13)
Loss from continuing operations	(459)	(723)
Loss from discontinued operations, net of taxes	(271)	(340)
Net loss	$ (730)	$ (1,063)
Net loss per common share: basic
Continuing operations (in Dollars per share)	$ (0.19)	$ (0.29)
Discontinued operations (in Dollars per share)	(0.11)	(0.14)
Net loss per common share: diluted
Continuing operations (in Dollars per share)	(0.19)	(0.29)
Discontinued operations (in Dollars per share)	$ (0.11)	$ (0.14)
Weighted average common shares outstanding used in computing net loss per common share
Basic (in Shares)	2,439,764	2,499,690
Diluted (in Shares)	2,439,764	2,499,690

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Loss from continuing operations	$ (459)	$ (723)
Loss from discontinued operations	(271)	(340)
Net loss	(730)	(1,063)
Other comprehensive income:
Unrealized gain (loss) on investments, net of taxes	(1)	1
Other comprehensive income (loss)	(1)	1
Comprehensive loss	$ (731)	$ (1,062)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Common stock	Treasury stock	Additional paid-in capital	Accum other comp inc.	Accum deficit	Total
Balance at Dec. 31, 2019	$ 29	$ (12,749)	$ 376,306	$ (1)	$ (330,340)	$ 33,245
Balance (in Shares) at Dec. 31, 2019	2,955,253	(253,082)
Stock-based compensation			168			168
Restricted stock issued			30			30
Restricted stock issued (in Shares)	3,597
Common stock issued, net of shares withheld for employee taxes			(48)			(48)
Common stock issued, net of shares withheld for employee taxes (in Shares)	12,433
Purchase of treasury stock, at cost		$ (2,398)				(2,398)
Purchase of treasury stock, at cost (in Shares)		(295,946)
Unrealized gain on investments, net of tax				1		1
Net loss					(1,063)	(1,063)
Balance at Dec. 31, 2020	$ 29	$ (15,147)	376,456		(331,403)	29,935
Balance (in Shares) at Dec. 31, 2020	2,971,283	(549,028)
Stock-based compensation			371			371
Common stock issued, net of shares withheld for employee taxes			(187)			(187)
Common stock issued, net of shares withheld for employee taxes (in Shares)	24,397
Unrealized gain on investments, net of tax				(1)		(1)
Net loss					(730)	(730)
Balance at Dec. 31, 2021	$ 29	$ (15,147)	$ 376,640	$ (1)	$ (332,133)	$ 29,388
Balance (in Shares) at Dec. 31, 2021	2,995,680	(549,028)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Loss from continuing operations	$ (459)	$ (723)
Adjustments to reconcile net loss from continuing operations to net cash used in continuing operations
Depreciation and amortization	140	152
Net gain on sale or disposal of assets and subsidiary	(613)	(2,084)
Realized loss on equity investments		1,824
Stock-based compensation	371	199
Changes in operating assets and liabilities:
Accounts receivable	(236)	257
Inventories	356	630
Other inventory supplies	6
Prepaid expenses and other assets	108	199
Accounts payable	19	(258)
Accrued payroll	215	159
Corporate income and franchise taxes	19	10
Accrued real estate taxes	7	(43)
Advance payments	(16)	2
Accrued and other current liabilities	22	(143)
Net cash provided by (used in) operating activities from continuing operations	(61)	181
Cash flows from discontinued operations	(262)	116
Cash flows from investing activities
Purchases of assets		(2)
Proceeds from sale or disposal of assets	643	4,909
Proceeds from sale or disposal of subsidiary		744
Purchase of investments	(6)	(2,782)
Proceeds from sale of investments	3	1,667
Net cash provided by investing activities	640	4,536
Cash flows from financing activities
Taxes paid related to net share settlement of equity awards	(187)	(48)
Purchases of treasury stock		(2,399)
Net cash used in financing activities	(187)	(2,447)
Net effect of currency translation		(136)
Net increase in cash and cash equivalents	130	2,250
Cash and cash equivalents, beginning of year	11,130	8,880
Cash and cash equivalents, end of year	$ 11,260	$ 11,130

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of business Rubicon Technology, Inc. (“Rubicon” or the “Company”) currently consists of one operating subsidiary, Rubicon Technology Worldwide LLC (“RTW”). In June 2021 the operations of Rubicon DTP LLC (“Direct Dose Rx” or DDRX”) were discontinued. RTW is an advanced materials provider specializing in monocrystalline sapphire for applications in optical and industrial systems. RTW sells its products on a global basis to customers in North America, Europe and Asia. RTW maintains its operating facility in the Chicago metropolitan area. In June 2021 the operations of Direct Dose Rx were discontinued. The costs associated with such closure were not material. Direct Dose Rx was a specialized pharmacy that provided prescription medications, over-the-counter drugs and vitamins to patients being discharged from skilled nursing facilities and hospitals and directly to retail customers who want such medications delivered to their home. The delivered products were sorted by the dose, date, and time to be taken and come in easy-to-use perforated strip-packaging as opposed to separate pill bottles. Direct Dose Rx was licensed to operate in 11 states. The services offered by Direct Dose Rx benefited patients, skilled nursing facilities and hospitals by reducing the risk of hospital readmissions. Principles of consolidation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, Rubicon Technology Worldwide LLC, Rubicon Technology BP LLC, and Rubicon Sapphire Technology (Malaysia) SDN BHD., and the discontinued operations of Rubicon DTP LLC. In December 2020, the Company sold all of the outstanding shares of capital stock of its wholly owned subsidiary Rubicon Sapphire Technology (Malaysia) SDN BHD. In June 2021, the operations of Rubicon DTP LLC were discontinued. All intercompany transactions and balances have been eliminated in consolidation. A summary of the Company’s significant accounting policies applied in the preparation of the accompanying Consolidated Financial Statements follows. Cash and cash equivalents The Company considers all unrestricted highly liquid investments immediately available to be cash equivalents. Cash equivalents primarily consist of time deposits with banks, unsettled trades and brokerage money market accounts. Foreign currency translation and transactions The Company has determined that the functional currency of Rubicon Sapphire Technology (Malaysia) SDN BHD is the U.S. dollar. Rubicon Sapphire Technology (Malaysia) SDN BHD’s assets and liabilities are translated into U.S. dollars using the re-measurement method. Non-monetary assets are translated at historical exchange rates and monetary assets are translated at exchange rates existing at the respective balance sheet dates. Translation adjustments for Rubicon Sapphire Technology (Malaysia) SDN BHD are included in determining net income (loss) for the period. The results of operations are translated into U.S. dollars at the average exchange rates during the respective period. The Company records these gains and losses in other income. Foreign currency transaction gains and losses are generated from the effects of exchange rate changes on transactions denominated in a currency other than the functional currency of the Company, which is the U.S. dollar. Gains and losses on foreign currency transactions are generally required to be recognized in the determination of net income (loss) for the period. The Company records these gains and losses in other income. Investments We invest our available cash primarily in U.S. Treasury securities, investment grade commercial paper, FDIC guaranteed certificates of deposit, common stock, equity-related securities and corporate notes. Investments classified as available-for-sale debt securities are carried at fair value with unrealized gains and losses recorded in accumulated other comprehensive income (loss). Investments in equity securities are reported at fair value, with both realized and unrealized gains and losses recorded in other income (expenses), in the Consolidated Statements of Operations. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support the current operations are classified as short-term. The Company reviews its available-for-sale debt securities investments at the end of each quarter for other-than-temporary declines in fair value based on the specific identification method. The Company considers various factors in determining whether an impairment is other-than-temporary, including the severity and duration of the impairment, changes in underlying credit ratings, forecasted recovery, its ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. When the Company concludes that an other-than-temporary impairment has resulted, the difference between the fair value and carrying value is written off and recorded as a charge on the Consolidated Statements of Operations. As of December 31, 2021, and 2020, no impairment was recorded. Purchases of Equity Securities by the Issuer In November 2018, the Company’s Board of Directors authorized a program to repurchase up to $3,000,000 of its common stock. In July 2020, the Company used all of the original authorized $3,000,000. On December 14, 2020, Rubicon’s Board of Directors authorized an additional $3,000,000 for the repurchase of the Company’s common stock. The timing, price and volume of repurchases will be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time, through solicited or unsolicited transactions in the open market, in privately negotiated transactions or pursuant to a Rule 10b5-1 plan. The program may be terminated, suspended or modified at any time. There can be no assurance as to the number of shares of common stock repurchased. The Company records treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. During the year ended December 31, 2020, the Company repurchased 295,946 shares at an average price of $8.10 per share. There was no share repurchase activity during the year ended December 31, 2021, and the approximate value of shares that may yet be purchased under the program remains at $3,000,000. Accounts receivable The majority of the Company’s accounts receivable are due from defense subcontractors, industrial manufacturers, fabricators and resellers. Credit is extended based on an evaluation of the customer’s financial condition. Accounts receivable are due based on contract terms and at stated amounts due from customers, net of an allowance for doubtful accounts. Losses from credit sales are provided for in the financial statements. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time a customer’s account is past due, the customer’s current ability to pay and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they are deemed uncollectible and such write-offs, net of payments received, are recorded as a reduction to the allowance. Accounts receivable is comprised of a net total of $719,000 and $386,000 for the years ended December 31, 2021 and 2020, respectively. The breakdown of accounts receivable for continuing operations and discontinued operations is as follows: Year Ended December 31, 2021 2020 Continuing Operations: Trade receivables $ 732 $ 281 Allowance for doubtful accounts (7 ) (3 ) Discontinued Operations: Trade receivables 6 108 Allowance for doubtful accounts (12 ) - Balance of accounts receivable, net $ 719 $ 386 Inventories Inventories are valued at the lower of cost or net realizable value. Net realizable value is determined based on an estimated selling price in the ordinary course of business less reasonably predictable costs of completion and disposal. Raw materials cost is determined using the first-in, first-out method, and work-in-process and finished goods costs are determined on a standard cost basis, which includes materials, labor and overhead. The Company reduces the carrying value of its inventories for differences between the cost and the estimated net realizable value, taking into account usage, expected demand, technological obsolescence and other relevant information. The Company establishes inventory reserves when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based on customer specifications. The Company evaluates the ability to realize the value of its inventory based on a combination of factors, including forecasted sales, estimated current and future market value and changes in customers’ product specifications. The Company’s method of estimating excess and obsolete inventory has remained consistent for all periods presented. The excess and obsolete inventory reserve at December 31, 2021 was $7,749,000 million compared to $7,908,000 million at December 31, 2020. For the year ended December 31, 2021, we consumed inventory that had previously been reflected as excess or obsolete and recorded a reduction in the inventory reserve of $159,000 and a reduction to cost of goods sold for the same amount. For the year ended December 31, 2020, we consumed inventory that had previously been reflected as excess or obsolete and recorded a reduction in the inventory reserve of $44,000 and a reduction to cost of goods sold for the same amount The Company also carries a lower of cost or market inventory reserve based on net realizable value using most recent sales prices to determine market value. As of December 31, 2021 and 2020, the balance of the lower of cost or market reserve was $25,000 and $52,000, respectively, representing a decrease of $27,000 resulting from sales of related reserved inventory. In 2020 we sold inventory that was valued at the lower of cost or market resulting in a reduction in both the lower of cost or market inventory reserve and cost of goods sold of $21,000. In 2020 and 2021, the Company used some of its previously written down two-inch diameter core material in production of optical and industrial sapphire wafers and did not record any additional adjustments for the years ended December 31, 2020 and December 31, 2021. The Company evaluates the amount of raw material needed for future production based on expected crystal growth production needed to meet anticipated sales. The Company did not record any write-downs of its raw materials inventory for the years ended December 31, 2020 and December 31, 2021. Inventories are composed of the following: As of December 31, 2021 2020 (in thousands) Raw materials $ 468 $ 468 Work-in-process 328 614 Finished goods 330 459 $ 1,126 $ 1,541 As of December 31, 2021 and 2020, the Company made the determination that raw material inventories were such that the likelihood of significant usage within the current year was doubtful and reclassified such raw material inventories as non-current in the reported financial statements. Inventories of discontinued operations was approximately $0 and $59,000 at years ended December 31, 2021 and 2020, respectively. Other inventory supplies The Company’s other inventory supplies include stock of consumable assets and spare parts used in the manufacturing process. Assets held for sale An asset is considered to be held for sale when all of the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv) actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi) the asset is actively being marketed for sale at a price that is reasonable given its current market value. A long-lived asset classified as held for sale is measured at the lower of its carrying amount or fair value less cost to sell. If the long-lived asset is newly acquired, the carrying amount of the long-lived asset is established based on its fair value less cost to sell at the acquisition date. A long-lived asset is not depreciated or amortized while it is classified as held for sale. The Company entered into an agreement for the sale of its Malaysian facility in December 2019, which was completed in June 2020 for a net sale price of approximately $4,800,000 (based on the exchange rate on June 30, 2020 of $1=MYR4.27) after the payment of consent fees, real estate taxes, brokerage and legal fees, transfer and other expenses. The Company recorded a gain on the disposal of the Malaysian facility of approximately $1,800,000. In December, 2020, the Company completed the sale of all of the outstanding shares of capital stock (the “Capital Shares”) of its wholly owned subsidiary Rubicon Sapphire Technology (Malaysia) SDN. BHD. The company recorded a gain on the sale of $261,000. On February 7, 2022, we entered into a real estate sale contract to sell our parcel of land in Batavia, Illinois for $722,000 and expect our net proceeds, if the sale is consummated, after the payment of fees, real estate taxes, brokerage and legal fees, transfer and withholding taxes and other expenses to be approximately $600,000. The closing of the sale of the Property is subject to certain conditions precedent. There is currently no anticipated closing date. Property and equipment Property and equipment consisted of the following: As of December 31, 2021 2020 (in thousands) Machinery, equipment and tooling $ 3,296 $ 3,343 Buildings 1,711 1,711 Information systems 819 835 Land and land improvements 594 594 Furniture and fixtures 7 8 Total cost 6,427 6,491 Accumulated depreciation and amortization (4,126 ) (4,009 ) Property and equipment, net $ 2,301 $ 2,482 Property and equipment are carried at cost and depreciated over their estimated useful lives using the straight-line method. The cost of maintenance and repairs is charged to expense as incurred. Significant renewals and improvements are capitalized. Depreciation expense associated with property and equipment was $140,000 and $152,000 for the years ended December 31, 2021 and 2020, respectively. The estimated useful lives are as follows: Asset description Life Buildings 39 years Machinery, equipment and tooling 3-10 years Furniture and fixtures 7 years Information systems 3 years As of December 31, 2021 and 2020, the property and equipment of the discontinued operations was $0 and less than $41,000, respectively. Warranty cost The Company’s sales terms include a warranty that its products will meet certain specifications. The Company records a current liability for the expected cost of warranty-related claims at the time of sale. The warranty reserve is included in accrued and other current liabilities on the Consolidated Balance Sheets. The following table presents changes in the Company’s product warranty liability: Year Ended December 31, 2021 2020 (in thousands) Balance, beginning of period $ 1 $ 3 Charged to cost of sales (9 ) (20 ) Actual product warranty expenditures 9 18 Balance, end of period $ 1 $ 1 The Company does not provide maintenance or other services and it does not have sales that involve bill & hold arrangements, multiple elements or deliverables. However, the Company does provide product warranty for up to 90 days, for which the Company has accrued a warranty reserve of $1,000 and $1,000 for the years ended December 31, 2021 and 2020, respectively. Fair value of financial instruments The Company’s financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable. The carrying values of these assets and liabilities approximate their fair values due to the short-term nature of these instruments at December 31, 2021 and 2020. Concentration of credit risks and other risks and uncertainties Financial instruments that could potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, short-term investments and accounts receivable. As of December 31, 2021, the Company had $8,100,000 on deposit at financial institutions in excess of amounts insured by the FDIC. This compares to $8,000,000 as of December 31, 2020. The Company performs a periodic evaluation of these institutions for relative credit standing. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant risk of loss on these balances. The Company uses third parties for certain finishing functions for its products, including the slicing and polishing of its sapphire crystal inventory. These types of services are only available from a limited number of third parties. The Company’s ability to successfully outsource these finishing functions will substantially depend on its ability to develop, maintain and expand its strategic relationship with these third parties. As a result, the Company may be unable to meet the demand for its products, which could have a material adverse impact on the Company. Concentration of credit risk related to revenue and accounts receivable is discussed in Note 4. Revenue recognition Revenues recognized include product sales and billings for costs and fees for government contracts. Product Sales The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts with Customers The Company does not provide maintenance or other services and we do not have sales that involve multiple elements or deliverables. All of the Company’s revenue is denominated in U.S. dollars. Shipping and handling costs The Company records costs incurred in connection with shipping and handling of products as cost of goods sold. Amounts billed to customers in connection with these costs are included in revenue and are not material for any of the periods presented in the accompanying financial statements. Sales tax The Company collects and remits sales taxes on products sold to customers and reports such amounts under the net method in its Consolidated Statements of Operations and records a liability until remitted to the respective tax authority. Stock-based compensation The Company requires all share-based payments to employees, including grants of employee stock options, to be measured at fair value and expensed in the Consolidated Statements of Operations over the service period (generally the vesting period) of the grant. Expense is recognized in the Consolidated Statements of Operations for these share-based payments. The Company uses Black Scholes option pricing model in order to determine the fair value of stock option grants. Accounting for uncertainty in income taxes The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and/or penalties related to income tax matters in income tax expense. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the years ended December 31, 2021 and 2020. The Company is subject to taxation in the U.S., Malaysia and in a U.S. state jurisdiction. Due to the existence of NOL carryforwards, tax years ended December 31, 2001 through 2006, 2008, 2009 and 2012 through 2020 are open to examination by tax authorities for Federal purposes. Due to NOL carryforwards at the State level, tax years ended 2008, 2009 and 2012 through 2020 are open to examination by state tax authorities. Tax years 2013 through 2019 are open to examination by the Malaysia Inland Revenue Board. Income taxes Deferred tax assets and liabilities are provided for temporary differences between financial reporting and income tax bases of assets and liabilities, and are measured using the enacted tax rates and laws expected to be in effect when the differences will reverse. Deferred income taxes also arise from the future benefits of NOL carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. Full valuation allowances on net deferred tax assets are maintained until an appropriate level of profitability that generates taxable income is deemed sustainable or until a tax strategy is developed that would enable the Company to conclude that it is more likely than not that a portion of the deferred tax assets will be realizable. Based on an evaluation in accordance with the accounting standards, as of December 31, 2021 and 2020, a valuation allowance has been recorded against the net U.S. and Malaysia deferred tax assets in order to measure only the portion of the deferred tax assets that are more likely than not to be realized based on the weight of all the available evidence . Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and those differences could be material. Other comprehensive loss Comprehensive loss is defined as the change in equity of a business enterprise from transactions and other events from non-owner sources. Comprehensive loss includes net loss and other non-owner changes in equity that bypass the statement of operations and are reported in a separate component of equity. Net income (loss) per common share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of diluted common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted-average shares (a) any outstanding stock options based on the treasury stock method and (b) restricted stock units (“RSU”). Diluted net loss per common share was the same as basic net loss per common share for the years ended December 31, 2021 and December 31, 2020, because the effects of potentially dilutive securities were anti-dilutive. New accounting pronouncements adopted The Company has evaluated recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact the Company’s consolidated financial statements and related disclosures.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
SEGMENT INFORMATION	2. SEGMENT INFORMATION Revenue is attributed by geographic region based on ship-to location of the Company’s customers. The following table summarizes revenue by geographic region: Year Ended December 31, 2021 2020 (in thousands) North America $ 3,671 $ 3,189 Asia 349 405 Other 41 22 Total revenue $ 4,061 $ 3,616 The following table summarizes sales by product type: Year Ended December 31, 2021 2020 (in thousands) Optical $ 4,061 $ 3,611 Core - 5 Total revenue $ 4,061 $ 3,616 All of our assets were located in the United States for the years ended December 31, 2021 and 2020.

Investments

Investments	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	3. INVESTMENTS The Company invests available cash primarily in U.S. Treasury securities, investment grade commercial paper, FDIC guaranteed certificates of deposit, common stock, equity related securities and corporate notes. Investments classified as available-for-sale debt securities are carried at fair value with unrealized gains and losses recorded in accumulated other comprehensive income/(loss). Investments in equity securities are reported at fair value, with both realized and unrealized gains and losses recorded as unrealized gain/(loss) on investments and realized gain on investments, in other income/(expense), in the Consolidated Statements of Operations. Investments in which the Company has the ability and intent, if necessary, to liquidate are classified as short-term. The following table presents the amortized cost, and gross unrealized gains and losses on all securities at December 31, 2021: Gross Gross Amortized unrealized unrealized Fair cost gains losses value (in thousands) Short-term investments: U.S. Treasury securities $ 14,751 $ - $ - $ 14,751 Total short-term investments $ 14,751 $ - $ - $ 14,751 The following table presents the amortized cost, and gross unrealized gains and losses on all securities at December 31, 2020: Gross Gross Amortized unrealized unrealized Fair cost gains losses value (in thousands) Short-term investments: U.S. Treasury securities $ 14,748 $ - $ - $ 14,748 Total short-term investments $ 14,748 $ - $ - $ 14,748 The Company values its investments at fair value, defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: ● Level 1—Quoted prices in active markets for identical assets or liabilities. ● Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s fixed income available-for-sale securities consist of U.S. Treasury securities, high-quality investment grade commercial paper, FDIC guaranteed certificates of deposit, common stock, equity related securities and corporate notes. The Company values these securities based on pricing from pricing vendors, who may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. The valuation techniques used to measure the fair value of the Company’s financial instruments having Level 2 inputs were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models, such as discounted cash flow techniques. The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2021: Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents: Money market funds $ 3,137 $ - $ - $ 3,137 Investments: Available-for-sales securities—current: U.S. Treasury securities - 14,751 - 14,751 Total $ 3,137 $ 14,751 $ - $ 17,888 The following table summarizes the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2020: Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents: Money market funds $ 3,136 $ - $ - $ 3,136 Investments: Available-for-sales securities—current: U.S. Treasury securities - 14,748 - 14,748 Total $ 3,136 $ 14,748 $ - $ 17,884 There are no terms or conditions restricting the Company from redeeming any of its investments. In addition to the debt securities noted above, the Company had approximately $8,100,000 and $8,000,000 of time deposits included in cash and cash equivalents as of December 31, 2021 and 2020, respectively.

Discontinued Operations_ Closur

Discontinued Operations: Closure of Direct Dose Rx	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS: Closure of Direct Dose Rx	4. DISCONTINUED OPERATIONS: Closure of Direct Dose Rx On June 24, 2021, the Company’s Board of Directors decided effective immediately, to close its pharmacy operations dba Direct Dose Rx. Immediately thereafter, Direct Dose Rx began transitioning its customers to other providers and began the process of closing its operations. Direct Dose was launched as a start-up pharmacy primarily to deliver medications and vitamins to patients being discharged from skilled nursing facilities. The Company does not believe that the costs associated with such closure will be material. Based on the Company’s review and analysis of ASC 205-20 Presentation of Discontinued Operations it concluded to present the discontinued operations separately. Year Ended December 31, 2021 2020 (in thousands) Revenues (discontinued operations) $ 370 $ 851 Operating Expense (discontinued operations) 641 1,191 Loss from operations of discontinued operations, net of taxes $ (271 ) $ (340 )

Significant Customers

Significant Customers	12 Months Ended
	Dec. 31, 2021
Significant Customers Disclosure [Abstract]
SIGNIFICANT CUSTOMERS	5. SIGNIFICANT CUSTOMERS For the year ended December 31, 2021, the Company had three customers that accounted for approximately 22%, 12%, and 12% of its revenue from continuing operations. For the year ended December 31, 2020, the Company had four customers that accounted for approximately 21%, 13%, 11%, and 10% of its revenue from continuing operations. Customers individually representing more than 10% of trade receivables accounted for approximately 80% and 44% of accounts receivable as of December 31, 2021 and 2020, respectively.

Assets Held for Sale and Long-L

Assets Held for Sale and Long-Lived Assets	12 Months Ended
	Dec. 31, 2021
Disclosure Text Block Supplement [Abstract]
ASSETS HELD FOR SALE AND LONG-LIVED ASSETS	6. ASSETS HELD FOR SALE AND LONG-LIVED ASSETS When circumstances, such as adverse market conditions, indicate that the carrying value of a long-lived asset may be impaired, the Company performs an analysis to review the recoverability of the asset’s carrying value using estimates of the undiscounted cash flows (excluding interest charges) from the expected future operations of the asset. These estimates consider factors such as expected future operating income, operating trends and prospects, as well as the effects of demand, competition and other factors. If the analysis indicates that the carrying value is not recoverable from future cash flows, an impairment loss is recognized to the extent that the carrying value exceeds the estimated fair value. The estimated fair value of assets is determined using appraisal techniques which assume the highest and best use of the asset by market participants, considering the use of the asset that is physically possible, legally permissible, and financially feasible at the measurement date. Any impairment losses are recorded as operating expenses, which reduce net income. In connection with the Company’s decision in 2016 to limit its focus to the optical and industrial sapphire markets and exit the LED market, the Company developed a plan to close its Malaysia facility, scale down and consolidate remaining operations in the U.S. and sell additional assets that would not be needed. The Company evaluated its U.S. and Malaysia asset portfolios to identify assets needed for its current business strategy and excess assets that were no longer needed. The Company determined it had excess machinery, equipment and facilities. Excess U.S. and Malaysia assets were evaluated based on assuming an orderly liquidation plan, which considers economic obsolescence and sales of comparable equipment, as it is the Company’s intention to sell these assets. Additionally, the Company evaluated its U.S. assets continuing to be used in operations using a cost and market approach to determine the current fair value. In the year ended December 31, 2019, we completed the sale of the remaining excess equipment located in Malaysia for total consideration of $490,000. Such equipment had a total net book value of $188,000, thereby resulting in a gain on disposal of $302,000. The Company entered into an agreement for the sale of its Malaysian facility in December 2019, which was completed in June 2020. In June 2020, the Company completed the sale of its Malaysian facility for a net sale price of approximately $4,800,000 (based on the exchange rate on June 30, 2020 of $1=MYR4.27) after the payment of consent fees, real estate taxes, brokerage and legal fees, transfer and other expenses. The Company recorded a gain on the disposal of the Malaysian facility of approximately $1,800,000. In December, 2020, the Company completed the sale of all of the outstanding shares of capital stock (the “Capital Shares”) of its wholly owned subsidiary Rubicon Sapphire Technology (Malaysia) SDN. BHD. The company recorded a gain on the sale of $261,000. On February 7, 2022, we entered into a real estate sale contract to sell our parcel of land in Batavia, Illinois for $722,000 and expect our net proceeds, if the sale is consummated, after the payment of fees, real estate taxes, brokerage and legal fees, transfer and withholding taxes and other expenses to be approximately $600,000. The closing of the sale of the Property is subject to certain conditions precedent. There is currently no anticipated closing date.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	7. STOCKHOLDERS’ EQUITY Common stock At the Company’s annual meeting of stockholders held on May 3, 2017, the Company’s stockholders approved amendments to the Company’s Eighth Amended and Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to (i) effect a reverse stock split of the Company’s common stock; and (ii) decrease the Company’s authorized number of shares of common stock to three times the number of shares of the Company’s common stock outstanding immediately following the reverse stock split. On May 3, 2017, following the annual meeting, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to (a) implement the reverse stock split at a ratio of 1-for-10; and (b) to reduce the number of authorized shares of common stock from 40,000,000 to 8,200,000, consequently reducing the number of total authorized shares from 45,000,000 to 13,200,000. With the completion of the reverse stock split, the Company’s shares began trading above the required $1.00 per share closing bid price, as required by the Listing Qualifications Department of NASDAQ. The share information has been retroactively reflected for the effects of this reverse stock split for all periods presented. Preferred stock At the Company’s annual meeting of stockholders held on May 10, 2018, the Company’s stockholders approved an amendment to the Certificate of Incorporation to decrease the Company’s authorized number of shares of preferred stock from 5,000,000 shares to 1,000,000 shares. The Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to decrease the authorized number of preferred shares, consequently reducing the number of total authorized shares from 13,200,000 to 9,200,000. Common shares reserved As of December 31, 2021, the Company had reserved 32,080 shares of common stock for issuance upon the exercise of outstanding common stock options and vesting of RSUs. Also, 304,731 shares of the Company’s common stock were reserved for future grants of stock options and RSUs (or other similar equity instruments) under the Rubicon Technology, Inc. 2016 Stock Incentive Plan (the “2016 Plan”) as of December 31, 2021.

Stockholder Rights Agreement

Stockholder Rights Agreement	12 Months Ended
	Dec. 31, 2021
Stockholder Rights Agreement [Abstract]
STOCKHOLDER RIGHTS AGREEMENT	8. STOCKHOLDER RIGHTS AGREEMENT On December 18, 2017, the Company entered into a Section 382 Rights Agreement with American Stock Transfer & Trust Company, LLC, as Rights Agent (the “Rights Agreement”) in an effort to protect stockholder value by attempting to diminish the risk that the Company’s ability to use its net NOLs to reduce potential future federal income tax obligations may become substantially limited. The Company’s ability to utilize its NOLs may be substantially limited if the Company experiences an “ownership change” within the meaning of Section 382 of the Internal Revenue Code of 1986, as amended (the “IRC”). The Rights Agreement is intended to act as a deterrent to any person acquiring beneficial ownership of 4.9% or more of the Company’s outstanding common stock without the approval of the Company’s Board of Directors (the “Board”). The Board authorized the issuance of one Right for each outstanding share of common stock, par value $0.001 per share, of the Company, payable to stockholders of record date of the close of business on January 2, 2018. One Right will also be issued together with each share of the Company’s common stock issued after January 2, 2018 but before the Distribution Date (as defined below) and, in certain circumstances, after the Distribution Date. Subject to the terms, provisions and conditions of the Rights Agreement, if the Rights become exercisable, each Right would initially represent the right to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company (the “Series A Preferred Stock”) for a purchase price of $40.00. If issued, each one-thousandth of a share of Series A Preferred Stock would give the stockholder approximately the same dividend, voting and liquidation rights as does one share of common stock. However, prior to exercise, a Right does not give its holder any rights as a stockholder of the Company, including, without limitation, any dividend, voting or liquidation rights. The Rights will not be exercisable until the earlier of (i) ten business days after a public announcement that a person has become an “Acquiring Person” by acquiring beneficial ownership of 4.9% or more of outstanding common stock (or, in the case of a person that had beneficial ownership of 4.9% or more of the outstanding common stock as of the close of business on December 18, 2017, by obtaining beneficial ownership of any additional shares of common stock representing 0.5% or more of the shares of common stock then outstanding (other than pursuant to a dividend or distribution paid or made by the Company on the outstanding shares of the common stock or pursuant to a split or subdivision of the outstanding shares of common stock) at a time such person still beneficially owns 4.9% or more of the outstanding common stock), and (ii) ten business days (or such later date as may be specified by the Board prior to such time as any person becomes an Acquiring Person) after the commencement of a tender or exchange offer by or on behalf of a person that, if completed, would result in such person becoming an Acquiring Person (the “Distribution Date”). Until the Distribution Date, common stock certificates or the ownership statements issued with respect to uncertificated shares of common stock will evidence the Rights. Any transfer of shares of common stock prior to the Distribution Date will also constitute a transfer of the associated Rights. After the Distribution Date, separate rights certificates will be issued and the Rights may be transferred other than in connection with the transfer of the underlying shares of common stock unless and until the Board has determined to effect an exchange pursuant to the Rights Agreement (as described below). In the event that a person becomes an Acquiring Person, each holder of a Right, other than Rights that are or, under certain circumstances, were beneficially owned by the Acquiring Person (which will thereupon become void), will thereafter have the right to receive upon exercise of a Right and payment of the purchase price, a number of shares of the Company’s common stock (or, in certain circumstances, cash, property or other securities of the Company) having a market value equal to two times the purchase price. However, Rights are subject to redemption and exchange at the option of the Company. In the event that, at any time following a person becoming an Acquiring Person, (i) the Company engages in a merger or other business combination transaction in which the Company is not the surviving corporation; (ii) the Company engages in a merger or other business combination transaction in which the Company is the surviving corporation and the common stock is changed or exchanged; or (iii) 50% or more of the Company’s assets, cash flow or earning power is sold or transferred, each holder of a Right (except Rights which have previously been voided) shall thereafter have the right to receive, upon exercise of the Right, common stock of the acquiring company having a value equal to two times the purchase price. At any time until the earlier of December 18, 2023, and ten calendar days following the first date of public announcement that a person has become an Acquiring Person or that discloses information which reveals the existence of an Acquiring Person or such earlier date as a majority of the Board becomes aware of the existence of an Acquiring Person, the Board may redeem the Rights in whole, but not in part, at a price of $0.001 per Right (the “Redemption Price”). The redemption of the Rights may be made effective at such time, on such basis and with such conditions as the Board in its sole discretion may establish. Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the only right of the holders of Rights will be to receive the Redemption Price. At any time after a person becomes an Acquiring Person, the Board may, at its option, exchange the Rights (other than Rights that have become void), in whole or in part, at an exchange ratio of one share of common stock, or a fractional share of Series A Preferred Stock (or of a share of a similar class or series of the Company’s preferred stock having similar rights, preferences and privileges) of equivalent value, per Right (subject to adjustment). Immediately upon an exchange of any Rights, the right to exercise such Rights will terminate and the only right of the holders of Rights will be to receive the number of shares of common stock (or fractional share of Series A Preferred Stock or of a share of a similar class or series of the Company’s preferred stock having similar rights, preferences and privileges) equal to the number of such Rights held by such holder multiplied by the exchange ratio. Each one one-thousandth of a share of Series A Preferred Stock, if issued: (i) will be nonredeemable and junior to any other series of preferred stock the Company may issue (unless otherwise provided in the terms of such other series), (ii) will entitle holders to preferential cumulative quarterly dividends in an amount per share of Series A Preferred Stock equal to the greater of (a) $1 or (b) 1,000 times the aggregate the dividends, if any, declared on one share of the Company’s common stock, (iii) will entitle holders upon liquidation (voluntary or otherwise) to receive $1,000 per share of Series A Preferred Stock plus an amount equal to accrued and unpaid dividends and distributions thereon, whether or not declared, (iv) will have the same voting power as one share of common stock, and (v) will entitle holders to a per share payment equal to the payment made on one share of the Company’s common stock, if shares of the common stock are exchanged via merger, consolidation, or a similar transaction. Because of the nature of the Series A Preferred Stock’s dividend, liquidation and voting rights, the value of a Unit of Series A Preferred Stock purchasable upon exercise of each Right should approximate the value of one share of common stock. The Rights and the Rights Agreement will expire on the earliest of (i) December 18, 2023, (ii) the time at which the Rights are redeemed pursuant to the Rights Agreement, (iii) the time at which the Rights are exchanged in full pursuant to the Rights Agreement, (iv) the date that the Board determines that the Rights Agreement is no longer necessary for the preservation of material valuable Tax Benefits, (v) the beginning of a taxable year of the Company to which the Board determines that no NOL tax benefits may be carried forward, and (vi) a determination by the Board, prior to the time any Person becomes an Acquiring Person, that the Rights Agreement and the Rights are no longer in the best interests of the Company and its stockholders. The Board may adjust the purchase price, the number of shares of Series A Preferred Stock or other securities or assets issuable and the number of outstanding Rights to prevent dilution that may occur as a result of certain events, including among others, a stock dividend, a stock split or a reclassification of the Series A Preferred Stock or common stock. With certain exceptions, no adjustments to the purchase price will be required until cumulative adjustments amount to at least 1% of the purchase price. For so long as the Rights are redeemable, the Board may supplement or amend any provision of the Rights Agreement in any respect without the approval of the holders of the Rights. From and after the time the Rights are no longer redeemable, the Board may supplement or amend the Rights Agreement only to cure an ambiguity, to alter time period provisions, to correct inconsistent provisions, or to make any additional changes to the Rights Agreement which the Company may deem necessary or desirable, but only to the extent that those changes do not impair or adversely affect any Rights holder (other than an Acquiring Person or any Affiliate or Associate of an Acquiring Person or certain of their transferees) and do not result in the Rights again becoming redeemable or the Rights Agreement again becoming amendable other than in accordance with this sentence. In connection with the adoption of the Rights Agreement and authorization and declaration of the dividend of the Rights, on December 18, 2017, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware. The Certificate of Designation became effective on December 18, 2017.

Stock Incentive Plans

Stock Incentive Plans	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK INCENTIVE PLANS	9. STOCK INCENTIVE PLANS In August 2007, the Company adopted the Rubicon Technology Inc. 2007 Stock Incentive Plan, which was amended and restated effective in March 2011 (the “2007 Plan”), and which allowed for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance awards and bonus shares. The maximum number of shares that could be awarded under the 2007 Plan was 440,769 shares. Options granted under the 2007 Plan entitle the holder to purchase shares of the Company’s common stock at the specified option exercise price, which could not be less than the fair market value of the common stock on the grant date. On June 24, 2016, the 2007 Plan terminated with the adoption of the Rubicon Technology, Inc. 2016 Stock Incentive Plan, (the “2016 Plan”). Any existing awards under the 2007 Plan remain outstanding in accordance with their current terms under the 2007 Plan. In June 2016, the Company’s stockholders approved adoption of the 2016 Plan effective as of March 17, 2016, which allows for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance awards and bonus shares. The Compensation Committee of the Board administers the 2016 Plan. The committee determines the type of award to be granted, the fair value, the number of shares covered by the award, and the time when the award vests and may be exercised. Pursuant to the 2016 Plan, 222,980 shares of the Company’s common stock plus any shares subject to outstanding awards under the 2007 Plan that subsequently expire unexercised, are forfeited without the delivery of shares or are settled in cash, will be available for issuance under the 2016 Plan. The 2016 Plan will automatically terminate on March 17, 2026, unless the Company terminates it sooner. The following table summarizes the activity of the stock incentive and equity plans: Shares Number of Weighted- Number of Number of Outstanding at January 1, 2020 276,386 22,839 $ 13.48 99,570 54,003 Granted (24,627 ) - - - 7,347 Exercised/issued - (2,250 ) - - (3,597 ) Canceled/forfeited 40,596 (489 ) 202.56 - (9,000 ) Outstanding at December 31, 2020 292,355 20,100 9.71 99,570 48,753 Granted (59,580 ) - - - 28,030 Exercised/issued - (15,000 ) 6.10 - (3,750 ) Canceled/forfeited 71,956 (1,050 ) 44.10 - (45,003 ) Outstanding at December 31, 2021 304,731 4,050 $ 14.16 99,570 28,030 There were no option grants made during 2021. At December 31, 2021, the exercise prices of outstanding options were as follows: Exercise price Number of Average Number of $6.10 - $8.34 3,250 5.16 3,250 $44.10 800 2.94 800 4,050 3.20 4,050 There were no options that became vested in the year ended 2021. The aggregate grant date fair value of the options that became vested in the year ended 2020 was $30,000. The following table summarizes the activity of non-vested options: Non- Weighted- Non-vested at January 1, 2020 4,866 $ 6.10 Granted - - Vested (4,866 ) 6.10 Cancelled - - Non-vested at December 31, 2020 - - Granted - - Vested - - Cancelled - - Non-vested at December 31, 2021 - $ - The Company’s aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock. Based on the fair value of the common stock at December 31, 2021 there was $7,000 of intrinsic value arising from 4,050 stock options exercisable or outstanding. The Company used historical stock prices as the basis for its volatility assumptions. The assumed risk-free rates were based on U.S. Treasury rates in effect at the time of grant with a term consistent with the expected option lives. The expected term for the year ended December 31, 2021, is based upon the Company’s median average life of its options. The forfeiture rate is based on the past history of forfeited options. The expense is being allocated using the straight-line method. For the year ended December 31, 2021, there was no recorded stock option compensation expense. As of December 31, 2021, there were no options granted, and all outstanding options awarded have been fully vested. For the year ended December 31, 2020, the Company recorded $14,000 of stock option compensation expense. The following table summarizes the award vesting terms for the RSUs granted in 2021: Number of RSUs Target price 12,500 $ 12.00 12,500 $ 13.00 The RSUs vest in the amounts set forth below on the first date the 15-trading day average closing price of the Company’s common stock equals or exceeds the corresponding target price for the common stock before December 28, 2025. On the date of grant of RSUs to a key executive, the closing price of the common stock was $9.20. During the twelve months ended December 31, 2021, neither tranche vested. The Company used Monte Carlo simulation model valuation technique to determine the fair value of RSUs granted because the awards vest based upon achievement of market price targets. The Monte Carlo simulation model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award and calculates the fair value of each RSU. The Company used the following assumptions in determining the fair value of the RSUs: Granted December Daily expected stock price volatility 2.1383 % Daily expected dividend yield 0.0 % Average daily risk-free interest rate 0.0039 % The daily expected stock price volatility is based on a four-year historical volatility of the Company’s common stock. The daily expected dividend yield is based on annual expected dividend payments. The average daily risk-free interest rate is based on the three-year treasury yield as of the grant date. Each of the tranches is calculated to have its own fair value and requisite service period. The fair value of each tranche is amortized over the requisite or derived service period, which is up to four years. The RSUs granted in December 2021 had a grant date fair value of $151,000. There were no grants with market price targets issued in the year ended December 31, 2021. A summary of the Company’s RSUs is as follows: RSUs Weighted-average Aggregate Non-vested RSUs as of January 1, 2020 54,003 $ 6.56 Granted 7,347 8.34 Vested (3,597 ) 8.34 Cancelled (9,000 ) 8.36 Non-vested RSUs as of December 31, 2020 48,753 6.34 Granted 28,030 9.90 Vested (3,750 ) 8.00 Cancelled (45,003 ) 7.45 Non-vested RSUs at December 31, 2021 28,030 $ 7.28 $ 204,062 The fair value of each RSU is the market price on the date of grant and is being recorded as compensation expense ratably over the vesting terms or the expected achievement of market price targets based on the Monte Carlo simulation model. For the years ended December 31, 2021 and 2020, the Company recorded $30,000 and $38,000 of RSU expense, respectively. The RSUs are forfeited by a participant upon termination for any reason, and there is no proportionate or partial vesting in the periods between the vesting dates. As of December 31, 2021, there was $151,000 of unrecognized compensation cost related to the non-vested RSUs. This cost will be recognized by the Company over a service period that was derived from the statistical valuation methods used to estimate the fair value of the RSUs at grant date. For the years ended December 31, 2021 and December 31, 2020, the Company recorded no compensation related to restricted stock. During the year ended December 31, 2020 the Company awarded approximately 17,000 shares to an officer of the Company with a fair value of $146,000.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”) which, among other provisions, reduced the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. The SEC issued guidance, Staff Accounting Bulletin 118, on accounting for the tax effects of the Act. The guidance allowed the Company to record provisional amounts for those impacts, with the requirement that the accounting be completed in a period not to exceed one year from the date of enactment. The Company has completed its accounting for the tax effects of enactment of the Act. The deemed inclusion from the repatriation tax increased from $3.9 million at the time of provision to $5.0 million at the time the calculation was finalized for the tax return. The increase of the inclusion related primarily to the refinement of Malaysia earnings and profits. As the Company is in a full valuation allowance position, an equal benefit adjustment was recorded for the impact of the increase of the deemed repatriation tax. Components of income before income taxes and the income tax provision are as follows: Income (loss) before income taxes Year Ended December 31, 2021 2020 (in thousands) U.S. $ (730 ) $ (3,060 ) Foreign 0 2,010 Total $ (730 ) $ (1,050 ) Income taxes Year Ended December 31, 2021 2020 (in thousands) Current U.S. $ 0 $ 0 State 0 0 Foreign 0 13 Total current income tax expense 0 13 Deferred U.S. 0 0 State 0 0 Foreign 0 0 Total deferred income tax expense (benefit) 0 0 Total income tax expense (benefit) $ 0 $ 13 The reconciliation of income tax computed at the federal statutory rate to income before taxes is as follows: Year Ended December 31, 2021 2020 U.S. federal statutory rate (21.0 )% (21.0 )% State taxes net of federal benefit (6.9 ) (18.2 ) Foreign rate differential and transactional tax 0.0 5.9 Tax credits 0.0 0.0 Valuation allowance 27.9 33.3 Other 0.0 1.0 0.0 % 1.0 % Deferred income taxes reflect the net tax effects of the temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred income taxes are as follows at December 31: 2021 2020 (in thousands) Deferred tax assets: Allowance for doubtful accounts $ 5 $ 1 Inventory reserves 3,033 3,096 Consumables excess reserve 162 167 Accrued liabilities 155 81 Warrant interest expense 195 195 Stock compensation expense 775 789 State net operating loss 13,358 14,476 Net operating loss carryforward 39,597 41,105 Capital loss carryforward 6,755 - Tax credits 669 710 Depreciation 423 1,000 Valuation allowance (65,079 ) (61,556 ) Total deferred tax assets 47 64 Deferred tax liability: Prepaid expenses (47 ) (64 ) Net deferred tax liability $ 0 $ 0 In February 2018, the FASB issued ASU No. 2018-02 (“ASU 2018-02), Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Comprehensive Income The Company adopted the guidance in ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes At December 31, 2021, we had separate Federal, Illinois and Indiana NOL carryforwards of $189 million, $181 million and $655,000, respectively. The Federal and Illinois NOLs began to expire in 2021 and the Indiana NOL will begin to expire in 2039. With the adoption of ASU 2016-09 in 2017, we recorded a deferred tax asset related to $26.4 million of unrecorded Federal and State NOLs attributable to stock option exercises. NOLs attributable to the stock option exercise were fully offset by the valuation allowance (as described above). We have recorded an uncertain tax position of $2.6 million that further reduces the net operating loss deferred tax assets reported in the financial statements. In addition, at December 31, 2021, we had Federal research and development credits of $662,000, which will begin to expire in 2028. The Company completed an analysis of the utilization of NOLs subject to limits based upon certain ownership changes as of December 31, 2021. The results of this analysis indicated no ownership change limiting the utilization of net operating losses and tax credits. The Company prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. At December 31, 2021 and 2020, the Company had $1.1 million of unrecognized tax benefits taken or expected to be taken in a tax return that have been recorded on the Company’s financial statements as an offset to the valuation allowance related to tax positions taken in 2012. It is not reasonably possible that the amount will change in the next twelve months. There were no material changes to prior year or current year positions taken during the year ended December 31, 2021. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the years ended December 31, 2021 and 2020. The Company files income tax returns in the United States federal jurisdiction and in a state jurisdiction. During 2009, the Company began foreign operations in Malaysia and is subject to local income taxes in that jurisdiction. The Company’s Malaysia tax returns for the periods ended December 31, 2010 through 2012 have been audited by the Malaysia Inland Revenue Board with no changes made to the taxable income for those years. All other tax years in Malaysia are open to examination by tax authorities. The Company’s federal tax returns for the periods ended December 31, 2010, 2008 and 2007 have been audited by the Internal Revenue Service (IRS) with no changes made to the Company’s taxable losses for those years. The Company’s state tax returns for the periods ended December 31, 2009 through 2012 have been audited by the Illinois Department of Revenue with no changes made to the Company’s taxable losses for those years. Due to the existence of NOL carryforwards, tax years ended December 31, 2006, 2008, 2009 and 2011 through 2020 are open to examination by tax authorities for Federal purposes. Due to NOL carryforwards at the State level, tax years ended 2012 through 2020 are open to examination by state tax authorities. Tax years 2013 through 2019 are open to examination by the Malaysia Inland Revenue Board. Due to the closing of the Rubicon Malaysia operations, the Company no longer considers the undistributed earnings of Rubicon Malaysia to be indefinitely reinvested. Upon liquidation of Rubicon Malaysia, it is anticipated any cash left after the liquidation will be brought back to the U.S. via a payment of principal towards the intercompany loan. A withholding tax may be payable to the Malaysian government on the interest portion of the loan. At December 31, 2021 and 2020, the Company accrued the withholding tax on the interest balance of the loan in the amount of $0 and $13,000, respectively, which represents the incremental tax.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. The full impact of the COVID-19 outbreak is unknown and cannot be reasonably estimated. The magnitude and duration of the COVID-19 outbreak, as well as other factors, could result in a material impact to the Company’s financial statements in future reporting periods. Operating Leases The Company adopted ASU 2016-02 in the first quarter of the fiscal year ending December 31, 2019. The adoption of ASU 2016-02 did not have a material impact on the Company’s consolidated financial statements, as the Company does not have any material lease agreements Rubicon DTP leases a building for its manufacturing and offices, however such lease was not considered material to the Company’s financial statements. Direct Dose’s net rent expense under operating leases in 2021 and 2020 amounted to $26,784 and $34,200, respectively. On January 6, 2021, Direct Dose entered into a one year lease for an aggregate commitment of approximately $35,500, which was terminated early per agreement with lessor as of September 9, 2021. As of December 31, 2020, Direct Dose’s operating lease for its facility was month-to-month. Litigation From time to time, the Company experiences routine litigation in the ordinary course of its business. There are no outstanding material matters as of December 31, 2021 and through the date of this filing.

Benefit Plan

Benefit Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
BENEFIT PLAN	12. BENEFIT PLAN The Company sponsors a 401(k) savings plan (the “Plan”). Employees are eligible to participate in the Plan upon reaching 18 years of age. Employees make contributions to the Plan through payroll deferrals. Employer matching contributions are discretionary. There were no employer matching contributions for the years ended December 31, 2021 and 2020.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS On February 7, 2022, we entered into a real estate sale contract to sell our parcel of land in Batavia, Illinois for $722,000 and expect our net proceeds, if the sale is consummated, after the payment of fees, real estate taxes, brokerage and legal fees, transfer and withholding taxes and other expenses to be approximately $600,000. The closing of the sale of the Property is subject to certain conditions precedent. There is currently no anticipated closing date. During February and March 2022, the Company settled liabilities that were accrued in prior years resulting in a gain of approximately $200,000.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Description of business	Description of business Rubicon Technology, Inc. (“Rubicon” or the “Company”) currently consists of one operating subsidiary, Rubicon Technology Worldwide LLC (“RTW”). In June 2021 the operations of Rubicon DTP LLC (“Direct Dose Rx” or DDRX”) were discontinued. RTW is an advanced materials provider specializing in monocrystalline sapphire for applications in optical and industrial systems. RTW sells its products on a global basis to customers in North America, Europe and Asia. RTW maintains its operating facility in the Chicago metropolitan area. In June 2021 the operations of Direct Dose Rx were discontinued. The costs associated with such closure were not material. Direct Dose Rx was a specialized pharmacy that provided prescription medications, over-the-counter drugs and vitamins to patients being discharged from skilled nursing facilities and hospitals and directly to retail customers who want such medications delivered to their home. The delivered products were sorted by the dose, date, and time to be taken and come in easy-to-use perforated strip-packaging as opposed to separate pill bottles. Direct Dose Rx was licensed to operate in 11 states. The services offered by Direct Dose Rx benefited patients, skilled nursing facilities and hospitals by reducing the risk of hospital readmissions.
Principles of consolidation	Principles of consolidation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, Rubicon Technology Worldwide LLC, Rubicon Technology BP LLC, and Rubicon Sapphire Technology (Malaysia) SDN BHD., and the discontinued operations of Rubicon DTP LLC. In December 2020, the Company sold all of the outstanding shares of capital stock of its wholly owned subsidiary Rubicon Sapphire Technology (Malaysia) SDN BHD. In June 2021, the operations of Rubicon DTP LLC were discontinued. All intercompany transactions and balances have been eliminated in consolidation. A summary of the Company’s significant accounting policies applied in the preparation of the accompanying Consolidated Financial Statements follows.
Cash and cash equivalents	Cash and cash equivalents The Company considers all unrestricted highly liquid investments immediately available to be cash equivalents. Cash equivalents primarily consist of time deposits with banks, unsettled trades and brokerage money market accounts.
Foreign currency translation and transactions	Foreign currency translation and transactions The Company has determined that the functional currency of Rubicon Sapphire Technology (Malaysia) SDN BHD is the U.S. dollar. Rubicon Sapphire Technology (Malaysia) SDN BHD’s assets and liabilities are translated into U.S. dollars using the re-measurement method. Non-monetary assets are translated at historical exchange rates and monetary assets are translated at exchange rates existing at the respective balance sheet dates. Translation adjustments for Rubicon Sapphire Technology (Malaysia) SDN BHD are included in determining net income (loss) for the period. The results of operations are translated into U.S. dollars at the average exchange rates during the respective period. The Company records these gains and losses in other income. Foreign currency transaction gains and losses are generated from the effects of exchange rate changes on transactions denominated in a currency other than the functional currency of the Company, which is the U.S. dollar. Gains and losses on foreign currency transactions are generally required to be recognized in the determination of net income (loss) for the period. The Company records these gains and losses in other income.
Investments	Investments We invest our available cash primarily in U.S. Treasury securities, investment grade commercial paper, FDIC guaranteed certificates of deposit, common stock, equity-related securities and corporate notes. Investments classified as available-for-sale debt securities are carried at fair value with unrealized gains and losses recorded in accumulated other comprehensive income (loss). Investments in equity securities are reported at fair value, with both realized and unrealized gains and losses recorded in other income (expenses), in the Consolidated Statements of Operations. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support the current operations are classified as short-term. The Company reviews its available-for-sale debt securities investments at the end of each quarter for other-than-temporary declines in fair value based on the specific identification method. The Company considers various factors in determining whether an impairment is other-than-temporary, including the severity and duration of the impairment, changes in underlying credit ratings, forecasted recovery, its ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. When the Company concludes that an other-than-temporary impairment has resulted, the difference between the fair value and carrying value is written off and recorded as a charge on the Consolidated Statements of Operations. As of December 31, 2021, and 2020, no impairment was recorded.
Purchases of Equity Securities by the Issuer	Purchases of Equity Securities by the Issuer In November 2018, the Company’s Board of Directors authorized a program to repurchase up to $3,000,000 of its common stock. In July 2020, the Company used all of the original authorized $3,000,000. On December 14, 2020, Rubicon’s Board of Directors authorized an additional $3,000,000 for the repurchase of the Company’s common stock. The timing, price and volume of repurchases will be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time, through solicited or unsolicited transactions in the open market, in privately negotiated transactions or pursuant to a Rule 10b5-1 plan. The program may be terminated, suspended or modified at any time. There can be no assurance as to the number of shares of common stock repurchased. The Company records treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. During the year ended December 31, 2020, the Company repurchased 295,946 shares at an average price of $8.10 per share. There was no share repurchase activity during the year ended December 31, 2021, and the approximate value of shares that may yet be purchased under the program remains at $3,000,000.
Accounts receivable	Accounts receivable The majority of the Company’s accounts receivable are due from defense subcontractors, industrial manufacturers, fabricators and resellers. Credit is extended based on an evaluation of the customer’s financial condition. Accounts receivable are due based on contract terms and at stated amounts due from customers, net of an allowance for doubtful accounts. Losses from credit sales are provided for in the financial statements. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time a customer’s account is past due, the customer’s current ability to pay and the condition of the general economy and industry as a whole. The Company writes off accounts receivable when they are deemed uncollectible and such write-offs, net of payments received, are recorded as a reduction to the allowance. Accounts receivable is comprised of a net total of $719,000 and $386,000 for the years ended December 31, 2021 and 2020, respectively. The breakdown of accounts receivable for continuing operations and discontinued operations is as follows: Year Ended December 31, 2021 2020 Continuing Operations: Trade receivables $ 732 $ 281 Allowance for doubtful accounts (7 ) (3 ) Discontinued Operations: Trade receivables 6 108 Allowance for doubtful accounts (12 ) - Balance of accounts receivable, net $ 719 $ 386
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value. Net realizable value is determined based on an estimated selling price in the ordinary course of business less reasonably predictable costs of completion and disposal. Raw materials cost is determined using the first-in, first-out method, and work-in-process and finished goods costs are determined on a standard cost basis, which includes materials, labor and overhead. The Company reduces the carrying value of its inventories for differences between the cost and the estimated net realizable value, taking into account usage, expected demand, technological obsolescence and other relevant information. The Company establishes inventory reserves when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based on customer specifications. The Company evaluates the ability to realize the value of its inventory based on a combination of factors, including forecasted sales, estimated current and future market value and changes in customers’ product specifications. The Company’s method of estimating excess and obsolete inventory has remained consistent for all periods presented. The excess and obsolete inventory reserve at December 31, 2021 was $7,749,000 million compared to $7,908,000 million at December 31, 2020. For the year ended December 31, 2021, we consumed inventory that had previously been reflected as excess or obsolete and recorded a reduction in the inventory reserve of $159,000 and a reduction to cost of goods sold for the same amount. For the year ended December 31, 2020, we consumed inventory that had previously been reflected as excess or obsolete and recorded a reduction in the inventory reserve of $44,000 and a reduction to cost of goods sold for the same amount The Company also carries a lower of cost or market inventory reserve based on net realizable value using most recent sales prices to determine market value. As of December 31, 2021 and 2020, the balance of the lower of cost or market reserve was $25,000 and $52,000, respectively, representing a decrease of $27,000 resulting from sales of related reserved inventory. In 2020 we sold inventory that was valued at the lower of cost or market resulting in a reduction in both the lower of cost or market inventory reserve and cost of goods sold of $21,000. In 2020 and 2021, the Company used some of its previously written down two-inch diameter core material in production of optical and industrial sapphire wafers and did not record any additional adjustments for the years ended December 31, 2020 and December 31, 2021. The Company evaluates the amount of raw material needed for future production based on expected crystal growth production needed to meet anticipated sales. The Company did not record any write-downs of its raw materials inventory for the years ended December 31, 2020 and December 31, 2021. Inventories are composed of the following: As of December 31, 2021 2020 (in thousands) Raw materials $ 468 $ 468 Work-in-process 328 614 Finished goods 330 459 $ 1,126 $ 1,541 As of December 31, 2021 and 2020, the Company made the determination that raw material inventories were such that the likelihood of significant usage within the current year was doubtful and reclassified such raw material inventories as non-current in the reported financial statements. Inventories of discontinued operations was approximately $0 and $59,000 at years ended December 31, 2021 and 2020, respectively.
Other inventory supplies	Other inventory supplies The Company’s other inventory supplies include stock of consumable assets and spare parts used in the manufacturing process.
Assets held for sale	Assets held for sale An asset is considered to be held for sale when all of the following criteria are met: (i) management commits to a plan to sell the asset; (ii) it is unlikely that the disposal plan will be significantly modified or discontinued; (iii) the asset is available for immediate sale in its present condition; (iv) actions required to complete the sale of the asset have been initiated; (v) sale of the asset is probable and the completed sale is expected to occur within one year; and (vi) the asset is actively being marketed for sale at a price that is reasonable given its current market value. A long-lived asset classified as held for sale is measured at the lower of its carrying amount or fair value less cost to sell. If the long-lived asset is newly acquired, the carrying amount of the long-lived asset is established based on its fair value less cost to sell at the acquisition date. A long-lived asset is not depreciated or amortized while it is classified as held for sale. The Company entered into an agreement for the sale of its Malaysian facility in December 2019, which was completed in June 2020 for a net sale price of approximately $4,800,000 (based on the exchange rate on June 30, 2020 of $1=MYR4.27) after the payment of consent fees, real estate taxes, brokerage and legal fees, transfer and other expenses. The Company recorded a gain on the disposal of the Malaysian facility of approximately $1,800,000. In December, 2020, the Company completed the sale of all of the outstanding shares of capital stock (the “Capital Shares”) of its wholly owned subsidiary Rubicon Sapphire Technology (Malaysia) SDN. BHD. The company recorded a gain on the sale of $261,000. On February 7, 2022, we entered into a real estate sale contract to sell our parcel of land in Batavia, Illinois for $722,000 and expect our net proceeds, if the sale is consummated, after the payment of fees, real estate taxes, brokerage and legal fees, transfer and withholding taxes and other expenses to be approximately $600,000. The closing of the sale of the Property is subject to certain conditions precedent. There is currently no anticipated closing date.
Property and equipment	Property and equipment Property and equipment consisted of the following: As of December 31, 2021 2020 (in thousands) Machinery, equipment and tooling $ 3,296 $ 3,343 Buildings 1,711 1,711 Information systems 819 835 Land and land improvements 594 594 Furniture and fixtures 7 8 Total cost 6,427 6,491 Accumulated depreciation and amortization (4,126 ) (4,009 ) Property and equipment, net $ 2,301 $ 2,482 Property and equipment are carried at cost and depreciated over their estimated useful lives using the straight-line method. The cost of maintenance and repairs is charged to expense as incurred. Significant renewals and improvements are capitalized. Depreciation expense associated with property and equipment was $140,000 and $152,000 for the years ended December 31, 2021 and 2020, respectively. The estimated useful lives are as follows: Asset description Life Buildings 39 years Machinery, equipment and tooling 3-10 years Furniture and fixtures 7 years Information systems 3 years As of December 31, 2021 and 2020, the property and equipment of the discontinued operations was $0 and less than $41,000, respectively.
Warranty cost	Warranty cost The Company’s sales terms include a warranty that its products will meet certain specifications. The Company records a current liability for the expected cost of warranty-related claims at the time of sale. The warranty reserve is included in accrued and other current liabilities on the Consolidated Balance Sheets. The following table presents changes in the Company’s product warranty liability: Year Ended December 31, 2021 2020 (in thousands) Balance, beginning of period $ 1 $ 3 Charged to cost of sales (9 ) (20 ) Actual product warranty expenditures 9 18 Balance, end of period $ 1 $ 1 The Company does not provide maintenance or other services and it does not have sales that involve bill & hold arrangements, multiple elements or deliverables. However, the Company does provide product warranty for up to 90 days, for which the Company has accrued a warranty reserve of $1,000 and $1,000 for the years ended December 31, 2021 and 2020, respectively.
Fair value of financial instruments	Fair value of financial instruments The Company’s financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, and accounts payable. The carrying values of these assets and liabilities approximate their fair values due to the short-term nature of these instruments at December 31, 2021 and 2020.
Concentration of credit risks and other risks and uncertainties	Concentration of credit risks and other risks and uncertainties Financial instruments that could potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, short-term investments and accounts receivable. As of December 31, 2021, the Company had $8,100,000 on deposit at financial institutions in excess of amounts insured by the FDIC. This compares to $8,000,000 as of December 31, 2020. The Company performs a periodic evaluation of these institutions for relative credit standing. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant risk of loss on these balances. The Company uses third parties for certain finishing functions for its products, including the slicing and polishing of its sapphire crystal inventory. These types of services are only available from a limited number of third parties. The Company’s ability to successfully outsource these finishing functions will substantially depend on its ability to develop, maintain and expand its strategic relationship with these third parties. As a result, the Company may be unable to meet the demand for its products, which could have a material adverse impact on the Company. Concentration of credit risk related to revenue and accounts receivable is discussed in Note 4.
Revenue recognition	Revenue recognition Revenues recognized include product sales and billings for costs and fees for government contracts. Product Sales The Company recognizes revenue in accordance with ASC Topic 606, Revenue From Contracts with Customers The Company does not provide maintenance or other services and we do not have sales that involve multiple elements or deliverables. All of the Company’s revenue is denominated in U.S. dollars.
Shipping and handling costs	Shipping and handling costs
Sales tax	Sales tax The Company collects and remits sales taxes on products sold to customers and reports such amounts under the net method in its Consolidated Statements of Operations and records a liability until remitted to the respective tax authority.
Stock-based compensation	Stock-based compensation The Company requires all share-based payments to employees, including grants of employee stock options, to be measured at fair value and expensed in the Consolidated Statements of Operations over the service period (generally the vesting period) of the grant. Expense is recognized in the Consolidated Statements of Operations for these share-based payments. The Company uses Black Scholes option pricing model in order to determine the fair value of stock option grants.
Accounting for uncertainty in income taxes	Accounting for uncertainty in income taxes The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and/or penalties related to income tax matters in income tax expense. There were no interest or penalties related to income taxes that have been accrued or recognized as of and for the years ended December 31, 2021 and 2020. The Company is subject to taxation in the U.S., Malaysia and in a U.S. state jurisdiction. Due to the existence of NOL carryforwards, tax years ended December 31, 2001 through 2006, 2008, 2009 and 2012 through 2020 are open to examination by tax authorities for Federal purposes. Due to NOL carryforwards at the State level, tax years ended 2008, 2009 and 2012 through 2020 are open to examination by state tax authorities. Tax years 2013 through 2019 are open to examination by the Malaysia Inland Revenue Board.
Income taxes	Income taxes Deferred tax assets and liabilities are provided for temporary differences between financial reporting and income tax bases of assets and liabilities, and are measured using the enacted tax rates and laws expected to be in effect when the differences will reverse. Deferred income taxes also arise from the future benefits of NOL carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. Full valuation allowances on net deferred tax assets are maintained until an appropriate level of profitability that generates taxable income is deemed sustainable or until a tax strategy is developed that would enable the Company to conclude that it is more likely than not that a portion of the deferred tax assets will be realizable. Based on an evaluation in accordance with the accounting standards, as of December 31, 2021 and 2020, a valuation allowance has been recorded against the net U.S. and Malaysia deferred tax assets in order to measure only the portion of the deferred tax assets that are more likely than not to be realized based on the weight of all the available evidence .
Use of estimates	Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and those differences could be material.
Other comprehensive loss	Other comprehensive loss Comprehensive loss is defined as the change in equity of a business enterprise from transactions and other events from non-owner sources. Comprehensive loss includes net loss and other non-owner changes in equity that bypass the statement of operations and are reported in a separate component of equity.
Net income (loss) per common share	Net income (loss) per common share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of diluted common shares outstanding during the period. Diluted shares outstanding are calculated by adding to the weighted-average shares (a) any outstanding stock options based on the treasury stock method and (b) restricted stock units (“RSU”). Diluted net loss per common share was the same as basic net loss per common share for the years ended December 31, 2021 and December 31, 2020, because the effects of potentially dilutive securities were anti-dilutive.
New accounting pronouncements adopted	New accounting pronouncements adopted The Company has evaluated recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact the Company’s consolidated financial statements and related disclosures.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Accounts receivable for continuing operations and discontinued operations	Year Ended December 31, 2021 2020 Continuing Operations: Trade receivables $ 732 $ 281 Allowance for doubtful accounts (7 ) (3 ) Discontinued Operations: Trade receivables 6 108 Allowance for doubtful accounts (12 ) - Balance of accounts receivable, net $ 719 $ 386
Schedule of inventories	As of December 31, 2021 2020 (in thousands) Raw materials $ 468 $ 468 Work-in-process 328 614 Finished goods 330 459 $ 1,126 $ 1,541
Schedule of property and equipment	As of December 31, 2021 2020 (in thousands) Machinery, equipment and tooling $ 3,296 $ 3,343 Buildings 1,711 1,711 Information systems 819 835 Land and land improvements 594 594 Furniture and fixtures 7 8 Total cost 6,427 6,491 Accumulated depreciation and amortization (4,126 ) (4,009 ) Property and equipment, net $ 2,301 $ 2,482
Schedule of estimated useful lives	Asset description Life Buildings 39 years Machinery, equipment and tooling 3-10 years Furniture and fixtures 7 years Information systems 3 years
Schedule of product warranty liability	Year Ended December 31, 2021 2020 (in thousands) Balance, beginning of period $ 1 $ 3 Charged to cost of sales (9 ) (20 ) Actual product warranty expenditures 9 18 Balance, end of period $ 1 $ 1

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Summary of revenue by geographic region	Year Ended December 31, 2021 2020 (in thousands) North America $ 3,671 $ 3,189 Asia 349 405 Other 41 22 Total revenue $ 4,061 $ 3,616
Summary of sales by product type	Year Ended December 31, 2021 2020 (in thousands) Optical $ 4,061 $ 3,611 Core - 5 Total revenue $ 4,061 $ 3,616

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of amortized cost and gross unrealized losses on all securities	Gross Gross Amortized unrealized unrealized Fair cost gains losses value (in thousands) Short-term investments: U.S. Treasury securities $ 14,751 $ - $ - $ 14,751 Total short-term investments $ 14,751 $ - $ - $ 14,751 Gross Gross Amortized unrealized unrealized Fair cost gains losses value (in thousands) Short-term investments: U.S. Treasury securities $ 14,748 $ - $ - $ 14,748 Total short-term investments $ 14,748 $ - $ - $ 14,748
Schedule of financial assets measured at fair value on a recurring basis	Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents: Money market funds $ 3,137 $ - $ - $ 3,137 Investments: Available-for-sales securities—current: U.S. Treasury securities - 14,751 - 14,751 Total $ 3,137 $ 14,751 $ - $ 17,888 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents: Money market funds $ 3,136 $ - $ - $ 3,136 Investments: Available-for-sales securities—current: U.S. Treasury securities - 14,748 - 14,748 Total $ 3,136 $ 14,748 $ - $ 17,884

Discontinued Operations_ Clos_2

Discontinued Operations: Closure of Direct Dose Rx (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations	Year Ended December 31, 2021 2020 (in thousands) Revenues (discontinued operations) $ 370 $ 851 Operating Expense (discontinued operations) 641 1,191 Loss from operations of discontinued operations, net of taxes $ (271 ) $ (340 )

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of activity of stock incentive and equity plans	Shares Number of Weighted- Number of Number of Outstanding at January 1, 2020 276,386 22,839 $ 13.48 99,570 54,003 Granted (24,627 ) - - - 7,347 Exercised/issued - (2,250 ) - - (3,597 ) Canceled/forfeited 40,596 (489 ) 202.56 - (9,000 ) Outstanding at December 31, 2020 292,355 20,100 9.71 99,570 48,753 Granted (59,580 ) - - - 28,030 Exercised/issued - (15,000 ) 6.10 - (3,750 ) Canceled/forfeited 71,956 (1,050 ) 44.10 - (45,003 ) Outstanding at December 31, 2021 304,731 4,050 $ 14.16 99,570 28,030
Schedule of exercise prices of outstanding options	Exercise price Number of Average Number of $6.10 - $8.34 3,250 5.16 3,250 $44.10 800 2.94 800 4,050 3.20 4,050
Schedule of non-vested options	Non- Weighted- Non-vested at January 1, 2020 4,866 $ 6.10 Granted - - Vested (4,866 ) 6.10 Cancelled - - Non-vested at December 31, 2020 - - Granted - - Vested - - Cancelled - - Non-vested at December 31, 2021 - $ -
Schedule of award vesting terms for the RSUs granted	Number of RSUs Target price 12,500 $ 12.00 12,500 $ 13.00
Schedule of valuation technique to determine the fair value of RSU	Granted December Daily expected stock price volatility 2.1383 % Daily expected dividend yield 0.0 % Average daily risk-free interest rate 0.0039 %
Schedule of Company’s RSUs	RSUs Weighted-average Aggregate Non-vested RSUs as of January 1, 2020 54,003 $ 6.56 Granted 7,347 8.34 Vested (3,597 ) 8.34 Cancelled (9,000 ) 8.36 Non-vested RSUs as of December 31, 2020 48,753 6.34 Granted 28,030 9.90 Vested (3,750 ) 8.00 Cancelled (45,003 ) 7.45 Non-vested RSUs at December 31, 2021 28,030 $ 7.28 $ 204,062

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of income (loss) before income taxes	Year Ended December 31, 2021 2020 (in thousands) U.S. $ (730 ) $ (3,060 ) Foreign 0 2,010 Total $ (730 ) $ (1,050 )
Schedule of income taxes	Year Ended December 31, 2021 2020 (in thousands) Current U.S. $ 0 $ 0 State 0 0 Foreign 0 13 Total current income tax expense 0 13 Deferred U.S. 0 0 State 0 0 Foreign 0 0 Total deferred income tax expense (benefit) 0 0 Total income tax expense (benefit) $ 0 $ 13
Schedule of reconciliation of income tax computed at the federal statutory rate to income before taxes	Year Ended December 31, 2021 2020 U.S. federal statutory rate (21.0 )% (21.0 )% State taxes net of federal benefit (6.9 ) (18.2 ) Foreign rate differential and transactional tax 0.0 5.9 Tax credits 0.0 0.0 Valuation allowance 27.9 33.3 Other 0.0 1.0 0.0 % 1.0 %
Schedule of significant components of the Company’s net deferred income taxes	2021 2020 (in thousands) Deferred tax assets: Allowance for doubtful accounts $ 5 $ 1 Inventory reserves 3,033 3,096 Consumables excess reserve 162 167 Accrued liabilities 155 81 Warrant interest expense 195 195 Stock compensation expense 775 789 State net operating loss 13,358 14,476 Net operating loss carryforward 39,597 41,105 Capital loss carryforward 6,755 - Tax credits 669 710 Depreciation 423 1,000 Valuation allowance (65,079 ) (61,556 ) Total deferred tax assets 47 64 Deferred tax liability: Prepaid expenses (47 ) (64 ) Net deferred tax liability $ 0 $ 0

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	Feb. 07, 2022	Jul. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 14, 2020	Nov. 30, 2018
Summary of Significant Accounting Policies (Details) [Line Items]
Repurchase of common stock			$ 3,000,000
Original authorized amount		$ 3,000,000
Repurchased shares (in Shares)				295,946
Average price (in Dollars per share)				$ 8.1
Accounts receivable net total			719,000	$ 386,000
Excess and obsolete inventory reserve			7,749,000	7,908,000
Inventory reserve and cost of goods sold			159,000	44,000
Cost or market reserve			25,000	52,000
Decrease in inventory reserves			27,000	21,000
Inventories of discontinued operations			0	59,000
Gain on disposal income			1,800,000
Depreciation expense associated with property and equipment			140,000	152,000
Discontinued operations			0	41,000
Warranty reserve			1,000	1,000
Foreign Financial Institutions, Actual Deposits			$ 8,100,000
Cash, FDIC Insured Amount				$ 8,000,000
Settlement percentage			50.00%
Subsequent Event [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Other expenses	$ 600,000
Board of Directors [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Repurchase of common stock					$ 3,000,000	$ 3,000,000
Malaysia [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Sale price			$ 4,800,000
Gain on sale			$ 261,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Accounts receivable for continuing operations and discontinued operations - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of Accounts receivable for continuing operations and discontinued operations [Abstract]
Trade receivables	$ 732	$ 281
Allowance for doubtful accounts	(7)	(3)
Trade receivables	6	108
Allowance for doubtful accounts	(12)
Balance of accounts receivable, net	$ 719	$ 386

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of inventories - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of inventories [Abstract]
Raw materials	$ 468	$ 468
Work-in-process	328	614
Finished goods	330	459
Inventories	$ 1,126	$ 1,541

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total cost	$ 6,427	$ 6,491
Accumulated depreciation and amortization	(4,126)	(4,009)
Property and equipment, net	2,301	2,482
Machinery, equipment and tooling [Member]
Property, Plant and Equipment [Line Items]
Total cost	3,296	3,343
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total cost	1,711	1,711
Information systems [Member]
Property, Plant and Equipment [Line Items]
Total cost	819	835
Land and land improvements [Member]
Property, Plant and Equipment [Line Items]
Total cost	594	594
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Total cost	$ 7	$ 8

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives	12 Months Ended
	Dec. 31, 2021
Buildings [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Property and equipment, estimated useful lives	39 years
Furniture and fixtures [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Property and equipment, estimated useful lives	7 years
Information systems [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Property and equipment, estimated useful lives	3 years
Minimum [Member] | Machinery, equipment and tooling [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Property and equipment, estimated useful lives	3 years
Maximum [Member] | Machinery, equipment and tooling [Member]
Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives [Line Items]
Property and equipment, estimated useful lives	10 years

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details) - Schedule of product warranty liability - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of product warranty liability [Abstract]
Balance, beginning of period	$ 1	$ 3
Charged to cost of sales	(9)	(20)
Actual product warranty expenditures	9	18
Balance, end of period	$ 1	$ 1

Segment Information (Details) -

Segment Information (Details) - Schedule of revenue by geographic region - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Segment Information (Details) - Schedule of revenue by geographic region [Line Items]
Total revenue	$ 4,061	$ 3,616
North America [Member]
Segment Information (Details) - Schedule of revenue by geographic region [Line Items]
Total revenue	3,671	3,189
Asia [Member]
Segment Information (Details) - Schedule of revenue by geographic region [Line Items]
Total revenue	349	405
Other [Member]
Segment Information (Details) - Schedule of revenue by geographic region [Line Items]
Total revenue	$ 41	$ 22

Segment Information (Details)_2

Segment Information (Details) - Schedule of sales by product type - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue from External Customer [Line Items]
Total revenue	$ 4,061	$ 3,616
Optical [Member]
Revenue from External Customer [Line Items]
Total revenue	4,061	3,611
Core [Member]
Revenue from External Customer [Line Items]
Total revenue		$ 5

Investments (Details)

Investments (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Time deposits included in cash and cash equivalents	$ 8,100,000	$ 8,000,000

Investments (Details) - Schedul

Investments (Details) - Schedule of amortized cost and gross unrealized losses on all securities - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Short-term investments:
Amortized cost	$ 14,751	$ 14,748
Gross unrealized gains
Gross unrealized losses
Fair value	14,751	14,748
U.S. Treasury securities [Member]
Short-term investments:
Amortized cost	14,751	14,748
Gross unrealized gains
Gross unrealized losses
Fair value	$ 14,751	$ 14,748

Investments (Details) - Sched_2

Investments (Details) - Schedule of financial assets measured at fair value on a recurring basis - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Available-for-sales securities—current:
Total	$ 17,888	$ 17,884
U.S. Treasury securities [Member]
Available-for-sales securities—current:
Available-for-sale securities - current	14,751	14,748
Level 1 [Member]
Available-for-sales securities—current:
Total	3,137	3,136
Level 1 [Member] | U.S. Treasury securities [Member]
Available-for-sales securities—current:
Available-for-sale securities - current
Level 2 [Member]
Available-for-sales securities—current:
Total	14,751	14,748
Level 2 [Member] | U.S. Treasury securities [Member]
Available-for-sales securities—current:
Available-for-sale securities - current	14,751	14,748
Level 3 [Member]
Available-for-sales securities—current:
Total
Level 3 [Member] | U.S. Treasury securities [Member]
Available-for-sales securities—current:
Available-for-sale securities - current
Money market funds [Member]
Cash equivalents:
Cash equivalents	3,137	3,136
Money market funds [Member] | Level 1 [Member]
Cash equivalents:
Cash equivalents	3,137	3,136
Money market funds [Member] | Level 2 [Member]
Cash equivalents:
Cash equivalents
Money market funds [Member] | Level 3 [Member]
Cash equivalents:
Cash equivalents

Discontinued Operations_ Clos_3

Discontinued Operations: Closure of Direct Dose Rx (Details) - Schedule of discontinued operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of discontinued operations [Abstract]
Revenues (discontinued operations)	$ 370	$ 851
Operating Expense (discontinued operations)	641	1,191
Loss from operations of discontinued operations, net of taxes	$ (271)	$ (340)

Significant Customers (Details)

Significant Customers (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Customer One [Member] | Sales Revenue, Net [Member]
Significant Customers (Details) [Line Items]
Revenue from continuing operations, percentage	22.00%	21.00%
Customer Two [Member] | Sales Revenue, Net [Member]
Significant Customers (Details) [Line Items]
Revenue from continuing operations, percentage	12.00%	13.00%
Customer three [Member] | Sales Revenue, Net [Member]
Significant Customers (Details) [Line Items]
Revenue from continuing operations, percentage	12.00%	11.00%
Customer Four [Member] | Sales Revenue, Net [Member]
Significant Customers (Details) [Line Items]
Revenue from continuing operations, percentage		10.00%
Trade Receivables Accounted [Member]
Significant Customers (Details) [Line Items]
Revenue from continuing operations, percentage	10.00%
Trade Receivables Accounted [Member] | Customer individually [Member]
Significant Customers (Details) [Line Items]
Revenue from continuing operations, percentage	80.00%	44.00%

Assets Held for Sale and Long_2

Assets Held for Sale and Long-Lived Assets (Details) - USD ($)	Feb. 07, 2022	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Assets Held for Sale and Long-Lived Assets (Details) [Line Items]
Total consideration				$ 490,000
Gain on disposal		$ 1,800,000		302,000
Exchange rate description		the Company completed the sale of its Malaysian facility for a net sale price of approximately $4,800,000 (based on the exchange rate on June 30, 2020 of $1=MYR4.27) after the payment of consent fees, real estate taxes, brokerage and legal fees, transfer and other expenses. The Company recorded a gain on the disposal of the Malaysian facility of approximately $1,800,000.
Gain on sale			$ 261,000
Subsequent Event [Member]
Assets Held for Sale and Long-Lived Assets (Details) [Line Items]
Sale Contract	$ 722,000
Expected net proceeds	$ 600,000
Equipment [Member]
Assets Held for Sale and Long-Lived Assets (Details) [Line Items]
Net book value				$ 188,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	May 10, 2018
Stockholders' Equity (Details) [Line Items]
Common stock description	At the Company’s annual meeting of stockholders held on May 3, 2017, the Company’s stockholders approved amendments to the Company’s Eighth Amended and Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to (i) effect a reverse stock split of the Company’s common stock; and (ii) decrease the Company’s authorized number of shares of common stock to three times the number of shares of the Company’s common stock outstanding immediately following the reverse stock split. On May 3, 2017, following the annual meeting, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to (a) implement the reverse stock split at a ratio of 1-for-10; and (b) to reduce the number of authorized shares of common stock from 40,000,000 to 8,200,000, consequently reducing the number of total authorized shares from 45,000,000 to 13,200,000. With the completion of the reverse stock split, the Company’s shares began trading above the required $1.00 per share closing bid price, as required by the Listing Qualifications Department of NASDAQ. The share information has been retroactively reflected for the effects of this reverse stock split for all periods presented
Preferred stock, shares authorized	1,000,000	1,000,000
Reserved shares of common stock for issuance	32,080
Common stock reserved for future grants	304,731
Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized	13,200,000		5,000,000
Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized	9,200,000		1,000,000

Stockholder Rights Agreement (D

Stockholder Rights Agreement (Details) - $ / shares	1 Months Ended	12 Months Ended
	Dec. 18, 2017	Dec. 31, 2021
Stockholder Rights Agreement (Details) [Line Items]
Redemption price		$ 0.001
Percentage of purchase price		1.00%
Business Combination [Member]
Stockholder Rights Agreement (Details) [Line Items]
Acquiring beneficial ownership, description		ten business days after a public announcement that a person has become an “Acquiring Person” by acquiring beneficial ownership of 4.9% or more of outstanding common stock (or, in the case of a person that had beneficial ownership of 4.9% or more of the outstanding common stock as of the close of business on December 18, 2017, by obtaining beneficial ownership of any additional shares of common stock representing 0.5% or more of the shares of common stock then outstanding (other than pursuant to a dividend or distribution paid or made by the Company on the outstanding shares of the common stock or pursuant to a split or subdivision of the outstanding shares of common stock) at a time such person still beneficially owns 4.9% or more of the outstanding common stock)
Percentage of company assets		50.00%
Common Stock [Member]
Stockholder Rights Agreement (Details) [Line Items]
Outstanding share of common stock, par value		$ 0.001
Preferred Stock [Member]
Stockholder Rights Agreement (Details) [Line Items]
Preferred stock, par value		0.001
Board of Directors [Member]
Stockholder Rights Agreement (Details) [Line Items]
Beneficial ownership percentage	4.90%
Series A Preferred Stock [Member]
Stockholder Rights Agreement (Details) [Line Items]
Purchase price		$ 40
Dividends, description		(a) $1 or (b) 1,000 times the aggregate the dividends, if any, declared on one share of the Company’s common stock
Per share of series A preferred stock		$ 1,000

Stock Incentive Plans (Details)

Stock Incentive Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Aug. 31, 2007
Stock Incentive Plans (Details) [Line Items]
Common stock reserved for future issuance of awards (in Shares)	32,080
Aggregate grant date fair value of the options		$ 30,000
Fair value of common stock intrinsic value	$ 7,000
Stock options exercisable (in Shares)	15,000	2,250
Stock option compensation expense		$ 14,000
Closing price of common stock (in Dollars per share)	$ 9.2
Derived service period	4 years
RSU expense	$ 30,000	$ 38,000
Unrecognized compensation cost	$ 151,000
Shares awarded (in Shares)		17,000
Fair value		$ 146,000
2007 Stock Incentive Plan [Member]
Stock Incentive Plans (Details) [Line Items]
Maximum number of shares awarded or sold (in Shares)			440,769
2016 Plan [Member]
Stock Incentive Plans (Details) [Line Items]
Common stock reserved for future issuance of awards (in Shares)	222,980
Plan termination date, description	The 2016 Plan will automatically terminate on March 17, 2026, unless the Company terminates it sooner.
Stock options [Member]
Stock Incentive Plans (Details) [Line Items]
Stock options exercisable (in Shares)	4,050
Restricted Stock Units (RSUs) [Member]
Stock Incentive Plans (Details) [Line Items]
Grant date fair value of restricted stock units	$ 151,000

Stock Incentive Plans (Detail_2

Stock Incentive Plans (Details) - Schedule of activity of stock incentive and equity plans - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of activity of stock incentive and equity plans [Abstract]
Shares available for grant, Beginning Balance	292,355	276,386
Number of options outstanding, Beginning Balance	20,100	22,839
Weighted-average option exercise price, Beginning Balance (in Dollars per share)	$ 9.71	$ 13.48
Number of restricted stock shares issued, Beginning Balance	99,570	99,570
Number of RSUs outstanding, Beginning Balance	48,753	54,003
Shares available for grant, Ending Balance	304,731	292,355
Number of options outstanding, Ending Balance	4,050	20,100
Weighted-average option exercise price, Ending Balance (in Dollars per share)	$ 14.16	$ 9.71
Number of restricted stock shares issued, Ending Balance	99,570	99,570
Number of RSUs outstanding, Ending Balance	28,030	48,753
Shares available for grant, Granted	(59,580)	(24,627)
Number of options outstanding, Granted
Weighted-average option exercise price, Granted (in Dollars per share)
Number of restricted stock shares issued, Granted
Number of RSUs outstanding, Granted	28,030	7,347
Shares available for grant, Exercised/issued
Number of options outstanding, Exercised/issued	(15,000)	(2,250)
Weighted-average option exercise price, Exercised/issued (in Dollars per share)	$ 6.1
Number of restricted stock shares issued, Exercised/issued
Number of RSUs outstanding, Exercised/issued	(3,750)	(3,597)
Shares available for grant, Canceled/forfeited	71,956	40,596
Number of options outstanding, Canceled/forfeited	(1,050)	(489)
Weighted-average option exercise price, Canceled/forfeited (in Dollars per share)	$ 44.1	$ 202.56
Number of restricted stock shares issued, Canceled/forfeited
Number of RSUs outstanding, Canceled/forfeited	(45,003)	(9,000)

Stock Incentive Plans (Detail_3

Stock Incentive Plans (Details) - Schedule of exercise prices of outstanding options	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding	4,050
Average remaining contractual life (years)	3 years 2 months 12 days
Number of options exercisable	4,050
$6.10 - $8.34 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding	3,250
Average remaining contractual life (years)	5 years 1 month 28 days
Number of options exercisable	3,250
$6.10 - $8.34 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 6.1
$6.10 - $8.34 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	8.34
$44.10 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 44.1
Number of options outstanding	800
Average remaining contractual life (years)	2 years 11 months 8 days
Number of options exercisable	800

Stock Incentive Plans (Detail_4

Stock Incentive Plans (Details) - Schedule of non-vested options - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of non-vested options [Abstract]
Non-vested, Beginning balance		4,866
Weighted-average option exercise price, Beginning balance		$ 6.1
Non-vested options, Granted
Weighted-average option exercise price, Granted
Non-vested options, Vested		(4,866)
Weighted-average option exercise price, Vested		$ 6.1
Non-vested options, Cancelled
Weighted-average option exercise price, Cancelled
Non-vested, Ending balance
Weighted-average option exercise price, Ending balance

Stock Incentive Plans (Detail_5

Stock Incentive Plans (Details) - Schedule of award vesting terms for the RSUs granted	12 Months Ended
	Dec. 31, 2021$ / shares
Restricted Stock Units RSUs One [Member]
Stock Incentive Plans (Details) - Schedule of award vesting terms for the RSUs granted [Line Items]
Number of RSUs	$ 12,500
Target price	12
Restricted Stock Units RSUs Two [Member]
Stock Incentive Plans (Details) - Schedule of award vesting terms for the RSUs granted [Line Items]
Number of RSUs	12,500
Target price	$ 13

Stock Incentive Plans (Detail_6

Stock Incentive Plans (Details) - Schedule of valuation technique to determine the fair value of RSU	12 Months Ended
	Dec. 31, 2021
Schedule of valuation technique to determine the fair value of RSU [Abstract]
Daily expected stock price volatility	2.1383%
Daily expected dividend yield	0.00%
Average daily risk-free interest rate	0.0039%

Stock Incentive Plans (Detail_7

Stock Incentive Plans (Details) - Schedule of Company’s RSUs - Restricted Stock Units (RSUs) [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stock Incentive Plans (Details) - Schedule of Company’s RSUs [Line Items]
Non-vested RSUs outstanding, Beginning balance	48,753	54,003
Weighted-average price at time of grant, Beginning balance	$ 6.34	$ 6.56
Non-vested RSUs outstanding, Granted	28,030	7,347
Weighted-average price at time of grant, Granted	$ 9.9	$ 8.34
Non-vested RSUs outstanding, Vested	(3,750)	(3,597)
Weighted-average price at time of grant, Vested	$ 8	$ 8.34
Non-vested RSUs outstanding, Cancelled	(45,003)	(9,000)
Weighted-average price at time of grant, Cancelled	$ 7.45	$ 8.36
Non-vested RSUs outstanding, Ending balance	28,030	48,753
Weighted-average price at time of grant, Ending balance	$ 7.28	$ 6.34
Aggregate intrinsic value, Non-vested, Ending balance	$ 204,062

Income Taxes (Details)

Income Taxes (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 22, 2017	Dec. 31, 2021	Dec. 31, 2020
Income Taxes (Details) [Line Items]
Description of federal expire		The Federal and Illinois NOLs began to expire in 2021 and the Indiana NOL will begin to expire in 2039.
Deferred tax asset		$ 26,400,000
Uncertain tax		2,600,000
Research and development		662,000
Unrecognized tax			$ 1,100,000
Loan amount		0	$ 13,000
Federal [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforward		189,000,000
Illinois [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforward		181,000,000
Indiana [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforward		655,000
Maximum [Member]
Income Taxes (Details) [Line Items]
U.S. corporate tax rate	35.00%
Repatriation tax		5,000,000
Minimum [Member]
Income Taxes (Details) [Line Items]
U.S. corporate tax rate	21.00%
Repatriation tax		$ 3,900,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of income (loss) before income taxes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of income (loss) before income taxes [Abstract]
U.S.	$ (730)	$ (3,060)
Foreign	0	2,010
Total	$ (730)	$ (1,050)

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of income taxes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of income taxes [Abstract]
U.S.	$ 0	$ 0
State	0	0
Foreign	0	13
Total current income tax expense	0	13
U.S.	0	0
State	0	0
Foreign	0	0
Total deferred income tax expense (benefit)	0	0
Total income tax expense (benefit)	$ 0	$ 13

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of reconciliation of income tax computed at the federal statutory rate to income before taxes	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of reconciliation of income tax computed at the federal statutory rate to income before taxes [Abstract]
U.S. federal statutory rate	(21.00%)	(21.00%)
State taxes net of federal benefit	(6.90%)	(18.20%)
Foreign rate differential and transactional tax	0.00%	5.90%
Tax credits	0.00%	0.00%
Valuation allowance	27.90%	33.30%
Other	0.00%	1.00%
Effective income tax rate	0.00%	1.00%

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of significant components of the Company’s net deferred income taxes - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Allowance for doubtful accounts	$ 5	$ 1
Inventory reserves	3,033	3,096
Consumables excess reserve	162	167
Accrued liabilities	155	81
Warrant interest expense	195	195
Stock compensation expense	775	789
State net operating loss	13,358	14,476
Net operating loss carryforward	39,597	41,105
Capital loss carryforward	6,755
Tax credits	669	710
Depreciation	423	1,000
Valuation allowance	(65,079)	(61,556)
Total deferred tax assets	47	64
Prepaid expenses	(47)	(64)
Net deferred tax liability	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 06, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating leases expenses	$ 26,784	$ 34,200
Aggregate commitment for one year lease			$ 35,500

Benefit Plan (Details)

Benefit Plan (Details)	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Benefit plan, description	Employees are eligible to participate in the Plan upon reaching 18 years of age.

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Feb. 07, 2022	Mar. 31, 2022
Subsequent Events (Details) [Line Items]
Real estate sale contract	$ 722,000
Net proceeds	$ 600,000
Forecast [Member]
Subsequent Events (Details) [Line Items]
Prior years liabilities settlement		$ 200,000